《新股表現》聯易融(09959.HK)上市翌日股價逆市曾續漲逾8%
騰訊(00700.HK)持股逾17%的聯易融科技-W(09959.HK)繼上周五首掛日漲近一成後,上市翌日股價逆市曾續漲8.2%至20.9元(較上市價17.58元累漲近19%)遇壓,現造20.1元,續升4%,成交3,645萬股,涉資7.32億元。
聯易融是內地領先的供應鏈金融科技解決方案提供商。根據灼識諮詢數據,聯易融去年處理供應鏈金融交易金額達1,638億人民幣,在內地行業排名第一,市場份額20.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.